Lung Ablation Outcomes for Inoperable Stage IA Non-Small Cell Lung Cancer.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
170 patients with complete follow-up data, the 1-year and 3-year LPFS rates were 91.
I · Intervention 중재 / 시술
percutaneous cryoablation for biopsy-proven Stage IA NSCLC at a single institution between July 2020 and July 2025
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] Percutaneous cryoablation provides effective local control with a favorable safety profile in patients with medically inoperable Stage IA NSCLC particularly with tumor smaller than 2.0 cm. These results support further exploration of cryoablation as a primary treatment modality for this patient population.
[PURPOSE] To evaluate the effectiveness and safety outcomes of percutaneous cryoablation for Stage IA non-small cell lung cancer (NSCLC) in medically inoperable patients.
- p-value P = .001
APA
Rehman S, Naidu S, et al. (2026). Lung Ablation Outcomes for Inoperable Stage IA Non-Small Cell Lung Cancer.. Journal of vascular and interventional radiology : JVIR, 37(3), 107974. https://doi.org/10.1016/j.jvir.2025.107974
MLA
Rehman S, et al.. "Lung Ablation Outcomes for Inoperable Stage IA Non-Small Cell Lung Cancer.." Journal of vascular and interventional radiology : JVIR, vol. 37, no. 3, 2026, pp. 107974.
PMID
41453487 ↗
Abstract 한글 요약
[PURPOSE] To evaluate the effectiveness and safety outcomes of percutaneous cryoablation for Stage IA non-small cell lung cancer (NSCLC) in medically inoperable patients.
[MATERIALS AND METHODS] This retrospective study analyzed 176 consecutive patients who underwent percutaneous cryoablation for biopsy-proven Stage IA NSCLC at a single institution between July 2020 and July 2025. Inclusion criteria included tumor size ≤3 cm, medically inoperable disease or patient refusal of surgery, and an Eastern Cooperative Oncology Group (ECOG) performance status score of <2. Procedures were performed under computed tomography (CT) guidance with a standardized triple freeze-thaw protocol. Follow-up involved routine CT and positron emission tomography (PET) imaging at standardized intervals. Overall survival (OS) and local progression-free survival (LPFS) and adverse event rates were calculated using Kaplan-Meier and Cox proportional hazards models.
[RESULTS] Of the 170 patients with complete follow-up data, the 1-year and 3-year LPFS rates were 91.8% and 89.4%, respectively, whereas the overall local progression rate was 10.6%. OS rates were 100.0% at 1 year and 94.7% at 3 years. On multivariate analysis, only larger tumor size (Stage IA3 vs IA2) was a significant independent predictor of local progression (adjusted hazard ratio, 4.71; P = .001). Pneumothorax requiring intervention was the most common adverse event (17.6%), with no in-hospital deaths, air embolism, or massive pulmonary hemorrhage.
[CONCLUSIONS] Percutaneous cryoablation provides effective local control with a favorable safety profile in patients with medically inoperable Stage IA NSCLC particularly with tumor smaller than 2.0 cm. These results support further exploration of cryoablation as a primary treatment modality for this patient population.
[MATERIALS AND METHODS] This retrospective study analyzed 176 consecutive patients who underwent percutaneous cryoablation for biopsy-proven Stage IA NSCLC at a single institution between July 2020 and July 2025. Inclusion criteria included tumor size ≤3 cm, medically inoperable disease or patient refusal of surgery, and an Eastern Cooperative Oncology Group (ECOG) performance status score of <2. Procedures were performed under computed tomography (CT) guidance with a standardized triple freeze-thaw protocol. Follow-up involved routine CT and positron emission tomography (PET) imaging at standardized intervals. Overall survival (OS) and local progression-free survival (LPFS) and adverse event rates were calculated using Kaplan-Meier and Cox proportional hazards models.
[RESULTS] Of the 170 patients with complete follow-up data, the 1-year and 3-year LPFS rates were 91.8% and 89.4%, respectively, whereas the overall local progression rate was 10.6%. OS rates were 100.0% at 1 year and 94.7% at 3 years. On multivariate analysis, only larger tumor size (Stage IA3 vs IA2) was a significant independent predictor of local progression (adjusted hazard ratio, 4.71; P = .001). Pneumothorax requiring intervention was the most common adverse event (17.6%), with no in-hospital deaths, air embolism, or massive pulmonary hemorrhage.
[CONCLUSIONS] Percutaneous cryoablation provides effective local control with a favorable safety profile in patients with medically inoperable Stage IA NSCLC particularly with tumor smaller than 2.0 cm. These results support further exploration of cryoablation as a primary treatment modality for this patient population.